Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2016 064 950.0 |
96 | EP file number | EAKZ | 16 82 2558.9 |
86 | WO file number | WAKZ | PCT/US2016/064865 |
97 | EP publication number | EPN | 3384294 |
87 | WO publication number | WPN | 2017096331 |
54 | Designation/title | TI | VERFAHREN UND ZUSAMMENSETZUNGEN IN ZUSAMMENHANG MIT ZELLTHERAPIEASSOZIIERTER TOXIZITÄT |
51 | IPC main class | ICM (ICMV) | G01N 33/68 (2006.01) |
22 | DE application date | DAT | Dec 2, 2016 |
96 | EP application date | EAT | Dec 2, 2016 |
86 | WO application date | WAT | Dec 2, 2016 |
43 | Date of first publication | OT | Jun 8, 2017 |
| Date of publication of grant | PET | Oct 13, 2021 |
71/73 | Applicant/owner | INH | Fred Hutchinson Cancer Center, Seattle, WA, US; Juno Therapeutics, Inc., Seattle, WA, US |
72 | Inventor | IN | LI, He, Seattle, WA 98109, US; GILBERT, Mark J., Seattle, WA 98109, US; MALONEY, David, Seattle, WA 98109, US; RIDDELL, Stanley R., Seattle, WA 98109, US; TURTLE, Cameron J., Seattle, WA 98109, US |
74 | Representative | VTR | Müller-Boré & Partner Patentanwälte PartG mbB, 80639 München, DE |
| Address for service | | Müller-Boré & Partner Patentanwälte PartG mbB, 80639 München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 201662417284 P Nov 3, 2016
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 201562263612 P Dec 4, 2015
|
| Due date | FT FG | Dec 31, 2025 Annual fee for the 10th year
Patent fees |
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000003384294A1 Searchable text:
EP000003384294A1 Original document:
EP000003384294B1 Searchable text:
EP000003384294B1 Original document:
WO002017096331 Searchable text:
WO002017096331 |
43 | Date of first publication | EVT | Jun 8, 2017 |
| Date of the first transfer into DPMAregister | EREGT | Oct 10, 2018 |
| Date of the (most recent) update in DPMAregister | REGT | Nov 7, 2024 (Show all update days)(Hide all update days)- Nov 7, 2024
- Sep 19, 2024
- Procedures: Procedure relating to PCT application, Publication of PCT application, 08.06.2017: deleted
- May 9, 2024; Nov 9, 2023; Apr 6, 2023; Feb 24, 2023; Nov 10, 2022; Oct 6, 2022; Sep 1, 2022; Dec 7, 2021; Nov 11, 2021; Oct 28, 2021; Sep 25, 2021; Sep 23, 2021; Aug 26, 2021; Aug 22, 2019
- Historical data not available for this/these date(s)
- Oct 10, 2018
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 7)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Feb 23, 2023 |
| Issue number | HN | 14 |
| Year | PJ | 2023 |
| Publication date | VT | Apr 6, 2023 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
71/73 | Applicant/owner | INH | Fred Hutchinson Cancer Center, Seattle, WA, US; Juno Therapeutics, Inc., Seattle, WA, US |
71/73 | Previous applicant/owner | INHF | Fred Hutchinson Cancer Research Center, Seattle, WA, US, Juno Therapeutics, Inc., Seattle, WA, US |
| Date of update of the procedure | REGT | Apr 6, 2023 |